Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jun 05, 2026
Why VEGN ETF Is Rising: Semiconductor Strength Fuels a 15% Monthly Gain

Why VEGN ETF Is Rising: Semiconductor Strength Fuels a 15% Monthly Gain

Key Takeaways

  • US Vegan Climate ETF (VEGN) rose approximately 15% over the past 30 days, driven primarily by strong gains in technology holdings.
  • Over the past quarter, VEGN advanced more than 33%, reflecting a sustained recovery in large-cap growth equities aligned with its index criteria.
  • Top contributors included semiconductor and technology stocks such as Micron Technology and Broadcom, which benefited from sector momentum.
  • The ETF’s focus on U.S. large-cap companies screened for vegan and climate-conscious principles resulted in significant exposure to high-performing tech names.
  • Broader market trends favoring growth stocks and positive sentiment in the semiconductor industry supported the ETF’s upward trajectory.

Understanding VEGN’s Focus and Holdings

The US Vegan Climate ETF seeks to track the performance of the Beyond Investing US Vegan Climate Index. The index starts with the constituents of the Solactive U.S. Large Cap Index and applies screens to exclude companies involved in animal exploitation or significant environmental harm. The fund typically holds approximately 100 to 150 securities, with the largest exposures concentrated in the technology sector. As of recent data, top holdings included Micron Technology and Broadcom, which together accounted for a notable portion of assets. This structure provides concentrated exposure to innovative U.S. large-cap growth companies that meet the fund’s ethical and environmental criteria, helping explain its sensitivity to technology sector performance.

VEGN’s Recent Price Moves: 30 Days and the Quarter

Over the last 30 days, VEGN recorded a gain of approximately 15%, moving from around 69 to near 79.56. The advance was relatively steady, with consistent upward movement amid improving market conditions. Over the past quarter, the ETF rose more than 33%, advancing from approximately 59.63 in early March to the recent level near 79.56. The quarterly trend showed a clear recovery pattern, with accelerating gains in May that carried into early June. Both periods reflected trend-driven appreciation rather than high volatility or range-bound behavior. I also checked this using Tickeron’s AI Screener to see how the ETF compares to others in the industry.

Drivers Behind the 30-Day Advance

The primary catalyst for the 30-day advance was robust performance in the technology sector, particularly among semiconductor companies. Holdings such as Micron Technology and Broadcom delivered strong returns amid continued demand for advanced chips and artificial intelligence infrastructure. VEGN’s index methodology results in meaningful allocations to these names, directly linking their price gains to the ETF’s movement. Positive broader market sentiment toward growth equities and favorable economic data further supported investor appetite for large-cap technology stocks that align with the fund’s screening criteria. No significant fund outflows or adverse macro events disrupted the upward trend during this period.

Factors Supporting the Quarterly Performance

Over the full quarter, the ETF benefited from a broader rebound in U.S. large-cap growth stocks. Technology sector strength, driven by sustained investment in artificial intelligence and data center expansion, provided the dominant positive influence. VEGN’s emphasis on companies meeting vegan and climate-related screens naturally tilts the portfolio toward innovative firms in semiconductors and software, amplifying gains when these areas outperformed. Macroeconomic conditions, including stable growth expectations and moderating inflation concerns, created a supportive environment for equities. Institutional interest in thematic and ESG-aligned products also contributed to steady demand, reinforcing the cumulative upward movement across the three-month period.

Exploring Similar Opportunities with Tickeron’s AI Screener

In my research process, I often turn to Tickeron’s AI Screener to filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows users to scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The tool helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. I find it particularly useful for spotting additional opportunities that align with specific strategies like thematic or ESG-focused investing.

What to Watch in the VEGN Outlook

Investors should monitor ongoing developments in the semiconductor industry and broader technology sector performance, as these remain central to VEGN’s holdings. Key macroeconomic indicators, including interest rate decisions, inflation data, and economic growth reports, will influence sentiment toward growth equities. Attention to any shifts in fund flows for ESG or thematic ETFs, as well as company-specific news from major holdings, will provide insight into potential drivers. Risks include sector concentration and sensitivity to technology valuations, while catalysts could emerge from continued innovation in artificial intelligence and data infrastructure. I’m watching this closely as the next earnings season for key holdings unfolds.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations


Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.